Astaxanthin Ameliorates Inflammation, Oxidative Stress, and Reproductive Outcomes in Endometriosis Patients Undergoing Assisted Reproduction: A Randomized, Triple-blind Placebo-controlled Clinical Trial
Overview
Authors
Affiliations
Purpose: In a randomized, triple-blind, placebo-controlled clinical trial (RCT) including 50 infertile women with endometriosis candidate for assisted reproductive techniques (ART), we studied the effect of Astaxanthin (AST) on pro-inflammatory cytokines, oxidative stress (OS) markers, and early pregnancy outcomes.
Methods: Before and after 12 weeks of AST treatment (6 mg per day), blood serum and follicular fluid (FF) samples were collected from 50 infertile women with endometriosis stage III/IV undergoing ART. Pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and OS markers (malondialdehyde [MDA], superoxide dismutase [SOD], catalase [CAT], and total antioxidant capacity [TAC]) were measured in the serum and FF. ART outcomes were also compared between the groups.
Results: Increased serum levels of TAC (398.661 ± 57.686 . 364.746 ± 51.569; P = 0.004) and SOD (13.458 ± 7.276 . 9.040 ± 5.155; P = 0.010) were observed after AST therapy in the treatment group. Furthermore, serum MDA (14.619 ± 2.505 . 15.939 ± 1.512; P = 0.031) decreased significantly following antioxidant treatment. In addition, significantly lower serum levels of IL-1β (4.515 ± 0.907 . 6.8760 ± 0.8478; P = 0.000), IL-6 (5.516 ± 0.646 . 5.0543 ± 0.709; P = 0.024) and TNF-α (2.520 ± 0.525 . 2.968 ± 0.548; P = 0.038) were observed after AST treatment. In addition, AST supplementation led to an improved number of oocytes retrieved (14.60 ± 7.79 . 9.84 ± 6.44; P = 0.043), number of mature (MII) oocytes (10.48 ± 6.665 . 6.72 ± 4.3; P = 0.041), and high-quality embryos (4.52 ± 2.41 . 2.72 ± 2.40; P = 0.024).
Conclusion: AST pretreatment can modulate inflammation and OS in endometriosis-induced infertile patients. ART outcomes also improved after 12 weeks of AST therapy. Our results suggest that AST can be a potential therapeutic target for infertile patients with endometriosis undergoing ART.
He J, Zhong Y, Li Y, Liu S, Pan X Int J Mol Sci. 2025; 26(5).
PMID: 40076863 PMC: 11900623. DOI: 10.3390/ijms26052241.
Ferreira F, Teixeira J, Lidon F, Cagide F, Borges F, Pereira R Animals (Basel). 2025; 15(3).
PMID: 39943058 PMC: 11815877. DOI: 10.3390/ani15030289.
Deleu S, Becherucci G, Godny L, Mentella M, Petito V, Scaldaferri F Nutrients. 2024; 16(23).
PMID: 39683595 PMC: 11644409. DOI: 10.3390/nu16234201.
Qin Y, Yang X, Zhao Q, Tang X, Zhao H, Jiao Y Medicine (Baltimore). 2024; 103(49):e40528.
PMID: 39654212 PMC: 11630926. DOI: 10.1097/MD.0000000000040528.
Gil T, Sim H, Lee H, Ryu S, Baek J, Kim D Mar Drugs. 2024; 22(11).
PMID: 39590792 PMC: 11595552. DOI: 10.3390/md22110512.